Recruiting Clinical Trials

Displaying 221 - 227 of 227 result(s)
Study Title Condition Phase Location
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer BRAF V600 Colorectal Cancer Phase 1
  • Country: 
    United States
  • Country: 
    Australia
  • Country: 
    Belgium
  • Country: 
    More locations
A Randomized, Open Label, Multi-centre, Two-treatment, Two-period, Two-sequence, Two-stage, Multiple Dose, Steady-state, Crossover, Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (A ... Ovarian Cancer, Breast Cancer Phase 1
  • Country: 
    India
Survey Among Healthcare Professionals and MS Patients/Caregivers in Selected European Countries to Evaluate the Knowledge Required for the Safe Use of Mayzent Multiple Sclerosis Not Given
  • Country: 
    Switzerland
A Phase Ib/II, Open Label Study of Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation Acute Myeloid Leukemia Phase 1, Phase 2
  • Country: 
    France
  • Country: 
    Germany
  • Country: 
    Italy
  • Country: 
    More locations
A Real-life Study to Evaluate the Use of Adjuvant Treatment With Dabrafenib and Trametinib in Routine Practice in Patients With Completely Resected High-risk Stage III Melanoma Melanoma Not Given
  • Country: 
    Turkey
A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuc ... Progressive Supranuclear Palsy (PSP) Phase 1
  • Country: 
    United States
  • Country: 
    Canada
  • Country: 
    Germany
  • Country: 
    More locations
A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg® (Ribociclib), Piqray® (Alpelisib), Endocrine Therapy or Chemothe ... Breast Cancer Not Given
  • Country: 
    Russian Federation